Article 1
(13 Z )-hexadec-13-en-11-yn-1-yl acetate is approved as an active substance for use in biocidal products of product-type 19 subject to the conditions set out in the Annex.
Commission Implementing Regulation (EU) 2023/1079 of 2 June 2023 approving (13Z)-hexadec-13-en-11-yn-1-yl acetate as an active substance for use in biocidal products of product-type 19 in accordance with Regulation (EU) No 528/2012 of the European Parliament and of the Council (Text with EEA relevance)
Data as of 2026-07-04 · Compiled from an official source version. Later amendments or repeals may not be reflected; the official text prevails. · Read the official text ↗
(13 Z )-hexadec-13-en-11-yn-1-yl acetate is approved as an active substance for use in biocidal products of product-type 19 subject to the conditions set out in the Annex.
This Regulation shall enter into force on the twentieth day following that of its publication in the Official Journal of the European Union .
ANNEX Common Name IUPAC Name Identification Numbers Minimum degree of purity of the active substance ( 1 ) Date of approval Expiry date of approval Product type Specific conditions (13 Z )-Hexadec-13-en-11-yn-1-yl acetate IUPAC name: (13 Z )-hexadec-13-en-11-yn-1-yl acetate EC No: Not allocated CAS No: 78617-58-0 970 g/kg dry weight 1 June 2023 31 May 2033 19 The authorisation of biocidal products is subject to the following conditions: The product assessment shall pay particular attention to the exposures, the risks and the efficacy linked to any of the uses covered by an application for authorisation, but not addressed in the Union level risk assessment of the active substance. For uses leading to higher exposure of the users, by-standers or the environment compared to the Union level risk assessment of the active substance, applications for product authorisation shall contain all data required for active substances in accordance with Annex II to Regulation (EU) No 528/2012, subject to the possibilities of adaptation of the data requirements in accordance with Annex IV to that Regulation. ( 1 ) The purity indicated in this column was the minimum degree of purity of the active substance evaluated. The active substance in the product placed on the market can be of equal or different purity if it has been proven to be technically equivalent to the evaluated active substance.
Source: EUR-Lex (Publications Office of the EU), © European Union, reuse permitted under Commission Decision 2011/833/EU.